SCHEMBL5013511

SCHEMBL5013511

Cc1ccc(S(=O)(=O)Nc2ccccc2CNC(=O)c2cc(NC(=O)c3cc(F)c(F)cc3Cl)[nH]n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.44
MEN1 O00255 5/20 0.44
ALDH1A1 P00352 7/20 0.43
KDM4E B2RXH2 6/20 0.43
GPR27 Q9NS67 4/20 0.42
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 2/20 0.41
PKM P14618 1/20 0.41
PPARG P37231 1/20 0.41
HPGD P15428 3/20 0.41
GAA P10253 2/20 0.40
GALR3 O60755 1/20 0.40
USP2 O75604 1/20 0.40
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HTT P42858 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5010558 0.88 ALDH1A1 (0.52) KMT2AMEN1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5008235 0.84 PPARG (0.44) KMT2AMEN1ALDH1A1KDM4EPPARG
SCHEMBL5010356 0.83 PPARG (0.50) ALDH1A1KDM4EPPARGHPGDNPC1
SCHEMBL14587822 0.82 PPARG (0.43) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL5008267 0.81 PPARG (0.45) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL5010568 0.81 NPC1 (0.46) KMT2AMEN1ALDH1A1KDM4EMAPT
Hydrochloric Acid SCHEMBL5012282 0.81 PPARG (0.42) KMT2AMEN1ALDH1A1KDM4EMAPT
SCHEMBL5013431 0.81 NPC1 (0.49) MAPTSMN1; SMN2PPARGNPC1RAB9A
SCHEMBL14587706 0.80 PPARG (0.48) KMT2AMEN1ALDH1A1PPARGNPC1
SCHEMBL5009713 0.80 NTRK1 (0.44) KMT2AMEN1ALDH1A1SMN1; SMN2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL KMT2A 4487/4885MEN1 4075/4885ALDH1A1 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.